{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:32:02Z","timestamp":1767947522866,"version":"3.49.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"DOI":"10.7759\/cureus.101126","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:25:05Z","timestamp":1767936305000},"source":"Crossref","is-referenced-by-count":0,"title":["Secondary Prophylaxis With Bioequivalent Generic Letermovir in Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report"],"prefix":"10.7759","author":[{"given":"Abhijit","family":"Baheti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyash","family":"Bharat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-023-01654-1","article-title":"Cytomegalovirus reactivation as a risk factor for all-cause mortality in children undergoing hematopoietic stem cell transplantation: experience over two decades from a tertiary referral center in India","volume":"40","author":"Chakraborty S","year":"2024","unstructured":"Chakraborty S, Swaminathan VV, Ganesan K, et al.. Cytomegalovirus reactivation as a risk factor for all-cause mortality in children undergoing hematopoietic stem cell transplantation: experience over two decades from a tertiary referral center in India. Indian J Hematol Blood Transfus. 2024, 40:91-6. 10.1007\/s12288-023-01654-1","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.01.082","article-title":"Cytomegalovirus reactivations in allogeneic hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplantation cyclophosphamide","volume":"30","author":"Chor\u00e3o P","year":"2024","unstructured":"Chor\u00e3o P, Henriques M, Villalba M, et al.. Cytomegalovirus reactivations in allogeneic hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplantation cyclophosphamide. Transplant Cell Ther. 2024, 30:538.e1-538.e10. 10.1016\/j.jtct.2024.01.082","journal-title":"Transplant Cell Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1871","article-title":"Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality","volume":"73","author":"Akahoshi Y","year":"2021","unstructured":"Akahoshi Y, Kimura SI, Inamoto Y, et al.. Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2021, 73:620-8. 10.1093\/cid\/ciaa1871","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106860","article-title":"Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants","volume":"62","author":"Allaw F","year":"2023","unstructured":"Allaw F, Haddad SF, Zakhour J, Kanj SS. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants. Int J Antimicrob Agents. 2023, 62:106860. 10.1016\/j.ijantimicag.2023.106860","journal-title":"Int J Antimicrob Agents"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0860-8","article-title":"Letermovir: first global approval","volume":"78","author":"Kim ES","year":"2018","unstructured":"Kim ES. Letermovir: first global approval. Drugs. 2018, 78:147-52. 10.1007\/s40265-017-0860-8","journal-title":"Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02471-0","article-title":"Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative phase 3 study","volume":"28","author":"Ishida H","year":"2024","unstructured":"Ishida H, Goto N, Imamura R, et al.. Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative phase 3 study. Clin Exp Nephrol. 2024, 28:822-31. 10.1007\/s10157-024-02471-0","journal-title":"Clin Exp Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty FM","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, et al.. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017, 377:2433-44. 10.1056\/NEJMoa1706640","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo D","year":"2024","unstructured":"Russo D, Schmitt M, Pilorge S, et al.. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024, 11:127-35. 10.1016\/S2352-3026(23)00344-7","journal-title":"Lancet Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.07.016","article-title":"Results of a phase I\/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation","volume":"33","author":"Lim ZY","year":"2009","unstructured":"Lim ZY, Cook G, Johnson PR, et al.. Results of a phase I\/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leuk Res. 2009, 33:244-9. 10.1016\/j.leukres.2008.07.016","journal-title":"Leuk Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/420619-secondary-prophylaxis-with-bioequivalent-generic-letermovir-in-haploidentical-hematopoietic-stem-cell-transplantation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:25:06Z","timestamp":1767936306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/420619-secondary-prophylaxis-with-bioequivalent-generic-letermovir-in-haploidentical-hematopoietic-stem-cell-transplantation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.101126","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}